Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 264

1.
2.
3.

Pharmacoeconomic evaluation of dabigatran, rivaroxaban and apixaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement in Spain.

Gómez-Outes A, Avendaño-Solá C, Terleira-Fernández AI, Vargas-Castrillón E.

Pharmacoeconomics. 2014 Sep;32(9):919-36. doi: 10.1007/s40273-014-0175-5.

PMID:
24895235
4.

Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U.S. payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

Pharmacoeconomics. 2012 Feb 1;30(2):87-101. doi: 10.2165/11599370-000000000-00000.

PMID:
22187932
5.

Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.

Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.

Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. Review.

6.

Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.

Monreal M, Folkerts K, Diamantopoulos A, Imberti D, Brosa M.

Thromb Haemost. 2013 Nov;110(5):987-94. doi: 10.1160/TH12-12-0919. Epub 2013 Aug 22.

PMID:
23965805
7.

Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.

Wolowacz SE, Roskell NS, Maciver F, Beard SM, Robinson PA, Plumb JM, Dolan G, Brenkel IJ.

Clin Ther. 2009 Jan;31(1):194-212. doi: 10.1016/j.clinthera.2009.01.001.

PMID:
19243718
8.

Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective.

McDonald H, Diamantopoulos A, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J.

J Med Econ. 2012;15(5):817-28. doi: 10.3111/13696998.2012.684116. Epub 2012 Apr 24.

PMID:
22494267
9.

Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.

Haentjens P, De Groote K, Annemans L.

Arch Orthop Trauma Surg. 2004 Oct;124(8):507-17. Epub 2004 Sep 10.

PMID:
15365714
10.

Cost-effectiveness of low-molecular-weight heparin compared with aspirin for prophylaxis against venous thromboembolism after total joint arthroplasty.

Schousboe JT, Brown GA.

J Bone Joint Surg Am. 2013 Jul 17;95(14):1256-64. doi: 10.2106/JBJS.L.00400.

PMID:
23864173
11.

[Cost-effectiveness analysis of apixaban compared to dabigatran in the prevention of venous thromboembolism in patients subjected to total knee or hip replacement].

Gómez-Cerezo JF, Gómez-Arrayás I, Suárez-Fernández C, Betegón-Nicolás L, de Salas-Cansado M, Rubio-Terrés C.

Rev Esp Cir Ortop Traumatol. 2012 Nov-Dec;56(6):459-70. doi: 10.1016/j.recot.2012.07.009. Epub 2012 Sep 7. Spanish.

PMID:
23594943
12.

Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.

Kapoor A, Chuang W, Radhakrishnan N, Smith KJ, Berlowitz D, Segal JB, Katz JN, Losina E.

Pharmacoeconomics. 2010;28(7):521-38. doi: 10.2165/11535210-000000000-00000. Review.

13.

Comparative effectiveness of low-molecular-weight heparins versus other anticoagulants in major orthopedic surgery: a systematic review and meta-analysis.

Sobieraj DM, Coleman CI, Tongbram V, Chen W, Colby J, Lee S, Kluger J, Makanji S, Ashaye A, White CM.

Pharmacotherapy. 2012 Sep;32(9):799-808. doi: 10.1002/j.1875-9114.2012.01106.x. Epub 2012 Jun 28. Review.

PMID:
22744711
14.

A Canadian study of the cost-effectiveness of apixaban compared with enoxaparin for post-surgical venous thromboembolism prevention.

Revankar N, Patterson J, Kadambi A, Raymond V, El-Hadi W.

Postgrad Med. 2013 Jul;125(4):141-53. doi: 10.3810/pgm.2013.07.2686.

PMID:
23933902
15.

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.

Honorato J, Gómez-Outes A, Navarro-Quilis A, Martínez-González J, Rocha E, Planès A.

Pharmacoeconomics. 2004;22(13):885-94.

PMID:
15329033
16.

Extended dalteparin prophylaxis for venous thromboembolic events: cost-utility analysis in patients undergoing major orthopedic surgery.

Dranitsaris G, Stumpo C, Smith R, Bartle W.

Am J Cardiovasc Drugs. 2009;9(1):45-58. doi: 10.2165/00129784-200909010-00005.

PMID:
19178131
17.

Comparative effectiveness of new oral anticoagulants and standard thromboprophylaxis in patients having total hip or knee replacement: a systematic review.

Adam SS, McDuffie JR, Lachiewicz PF, Ortel TL, Williams JW Jr.

Ann Intern Med. 2013 Aug 20;159(4):275-84. doi: 10.7326/0003-4819-159-4-201308200-00008. Review.

18.

Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.

Duran A, Sengupta N, Diamantopoulos A, Forster F, Kwong L, Lees M.

J Med Econ. 2011;14(6):824-34. doi: 10.3111/13696998.2011.623203. Epub 2011 Oct 24.

PMID:
22023098
19.

Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis.

Neumann I, Rada G, Claro JC, Carrasco-Labra A, Thorlund K, Akl EA, Bates SM, Guyatt GH.

Ann Intern Med. 2012 May 15;156(10):710-9. doi: 10.7326/0003-4819-156-10-201205150-00421. Epub 2012 Mar 12. Review.

PMID:
22412038
20.

Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada.

Diamantopoulos A, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H.

Thromb Haemost. 2010 Oct;104(4):760-70. doi: 10.1160/TH10-01-0071. Epub 2010 Aug 30. Review.

PMID:
20806107
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk